Product Details
Place of Origin: China
Brand Name: BBCA
Certification: GMP
Model Number: BBCA180226050
Payment & Shipping Terms
Minimum Order Quantity: 1 KGS
Price: Negotiated
Packaging Details: 8kgs/10kgs/tin
Delivery Time: 10 DAYS AFTER PAYMENT
Payment Terms: L/C, T/T, , MoneyGram, L/C, T/T, , MoneyGram
Supply Ability: 500 KGS PER MONTH
CAS No.: |
57469-77-9 |
Place Of Origin: |
China (Mainland) |
Type: |
Antibiotic And Antimicrobial Agents |
Grade Standard: |
Medicine Grade |
Usage: |
Animal Pharmaceuticals |
Brand Name: |
BBCA |
Purity: |
99%min |
CAS No.: |
57469-77-9 |
Place Of Origin: |
China (Mainland) |
Type: |
Antibiotic And Antimicrobial Agents |
Grade Standard: |
Medicine Grade |
Usage: |
Animal Pharmaceuticals |
Brand Name: |
BBCA |
Purity: |
99%min |
99% Min API Ibuprofen Lysine / Ibuprofen Powder For Oral CAS No 57469-77-9
Specification
Ibuprofen Lysine
Melting point:167℃
Acidity:6.83
Free Ibuprofen:0.4%
Loss on drying:0.1%
Heavy Metals:<20ppm
Ibuprofen(C13H18O2):55.22%
Arginine(C6H14N4O2):45.39%
Function:1.Ibuprofen is used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis and rheumatoid arthritis.
2. It is also used to relieve mild to moderate pain, including menstrual pain. Nonprescription
3. ibuprofen is used to reduce fever and to relieve mild pain from headaches, muscle aches, arthritis, menstrual periods, the common cold, toothaches, and backaches.
Certificate of Analysis of Ibuprofen BP2007:
ITEMS | SPECIFICATIONS | RESULTS |
Appearance | White, crystalline powder or colorless crystals | Passes |
Identification | Accord With BP2007 | Passes |
Assay | 98.5%~101.0% | 99.97% |
Melting point | 75°C~78°C | 77°C |
Optical rotation | -0.05°~+0.05° | 0.00° |
Heavy metals | ≤ 0.001% | <0.001% |
Related substances | ||
Impurity B | ≤ 0.3% | Passes |
Any other impurity | ≤ 0.3% | Passes |
Total of all impurities apart from impurity B | ≤ 0.7% | Passes |
Impurity F | ≤ 0.1% | Not detected |
Sulphated ash | ≤ 0.1% | 0.02% |
Appearance of solution | Accord With BP2007 | Passes |
Conclusion: COMPLY WITH BP2007 |